Pfizer (PFE) Financials

$22.80 +0.41 (+1.83%)

As of 03:59 PM Eastern

Annual Income Statements for Pfizer

This table shows Pfizer's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	6,960	7,215	21,308	11,153	16,026	9,159	21,979	31,372	2,119	8,031
Consolidated Net Income / (Loss)	6,986	7,246	21,355	11,188	16,056	9,195	22,025	31,407	2,158	8,062
Net Income / (Loss) Continuing Operations	6,975	7,229	21,353	3,861	10,738	6,666	22,459	31,401	2,172	8,051
Total Pre-Tax Income	8,965	8,351	12,305	3,594	11,321	7,036	24,311	34,729	1,058	8,023
Total Operating Income	11,824	12,145	13,720	5,672	6,710	8,250	19,433	35,789	1,279	12,411
Total Gross Profit	39,203	40,502	41,316	31,838	32,851	33,167	50,467	66,831	34,599	45,776
Total Revenue	48,851	52,824	52,544	40,825	40,905	41,651	81,288	101,175	59,553	63,627
Operating Revenue	48,851	52,824	52,544	40,825	40,905	41,651	81,288	101,175	59,553	63,627
Total Cost of Revenue	9,648	12,322	11,228	8,987	8,054	8,484	30,821	34,344	24,954	17,851
Operating Cost of Revenue	9,648	12,322	11,228	8,987	8,054	8,484	30,821	34,344	24,954	17,851
Total Operating Expenses	27,379	28,357	27,596	26,166	26,141	24,917	31,034	31,042	33,320	33,365
Selling, General & Admin Expense	14,809	14,844	14,804	12,612	12,726	11,597	12,703	13,677	14,771	14,730
Research & Development Expense	7,690	7,892	7,683	7,760	8,385	9,393	13,829	12,381	10,873	10,930
Amortization Expense	3,728	4,056	4,758	4,736	4,429	3,348	3,700	3,609	4,733	5,286
Restructuring Charge	1,152	1,565	351	1,058	601	579	802	1,375	2,943	2,419
Total Other Income / (Expense), net	-2,860	-3,794	-1,416	-2,077	4,610	-1,213	4,878	-1,062	-222	-4,388
Other Income / (Expense), net	-2,860	-3,794	-1,416	-2,077	-3,497	-1,213	4,878	-1,062	-222	-4,388
Income Tax Expense	1,990	1,123	-9,049	-266	583	370	1,852	3,328	-1,115	-28
Net Income / (Loss) Discontinued Operations	11	17	2.00	7,328	5,318	2,529	-434	6.00	-15	11
Net Income / (Loss) Attributable to Noncontrolling Interest	26	31	47	36	29	36	45	35	39	31
Basic Earnings per Share	$1.13	$1.18	$3.57	$1.90	$2.88	$1.65	$3.92	$5.59	$0.38	$1.42
Weighted Average Basic Shares Outstanding	6.18B	6.09B	5.97B	5.87B	5.57B	5.56B	5.60B	5.61B	5.64B	5.66B
Diluted Earnings per Share	$1.11	$1.17	$3.52	$1.87	$2.82	$1.63	$3.85	$5.47	$0.37	$1.41
Weighted Average Diluted Shares Outstanding	6.26B	6.16B	6.06B	5.98B	5.68B	5.63B	5.71B	5.73B	5.71B	5.70B
Weighted Average Basic & Diluted Shares Outstanding	6.18B	6.11B	5.97B	5.87B	5.55B	5.58B	5.62B	5.62B	5.65B	5.67B
Cash Dividends to Common per Share	$1.12	$1.22	$1.30	$1.38	$1.46	$1.53	$1.57	$1.61	$1.65	$1.69

This table shows Pfizer's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	8,608	4,994	5,543	2,327	-2,382	-3,369	3,115	41	4,465	410
Consolidated Net Income / (Loss)	8,623	5,003	5,556	2,338	-2,376	-3,360	3,123	48	4,473	418
Net Income / (Loss) Continuing Operations	8,645	5,000	5,555	2,340	-2,388	-3,335	3,128	31	4,481	411
Total Pre-Tax Income	9,001	5,231	6,270	2,269	-3,352	-4,129	3,421	-103	4,715	-10
Total Operating Income	8,943	5,226	6,544	2,194	-3,171	-4,288	4,102	1,003	4,959	2,347
Total Gross Profit	16,575	15,485	13,600	9,770	4,222	7,007	11,500	9,983	12,439	11,854
Total Revenue	22,638	25,134	18,486	13,007	13,491	14,569	14,879	13,283	17,702	17,763
Operating Revenue	22,638	25,134	18,486	13,007	13,491	14,569	14,879	13,283	17,702	17,763
Total Cost of Revenue	6,063	9,649	4,886	3,237	9,269	7,562	3,379	3,300	5,263	5,909
Operating Cost of Revenue	6,063	9,649	4,886	3,237	9,269	7,562	3,379	3,300	5,263	5,909
Total Operating Expenses	7,632	10,259	7,056	7,576	7,393	11,295	7,398	8,980	7,480	9,507
Selling, General & Admin Expense	3,391	4,645	3,418	3,497	3,281	4,575	3,495	3,717	3,244	4,274
Research & Development Expense	3,220	3,689	2,526	2,681	2,778	2,888	2,493	2,702	2,611	3,124
Amortization Expense	822	1,130	1,103	1,184	1,179	1,267	1,308	1,307	1,312	1,359
Restructuring Charge	199	795	9.00	214	155	2,565	102	1,254	313	750
Total Other Income / (Expense), net	59	1.00	-275	75	-181	159	-680	-1,107	-243	-2,358
Other Income / (Expense), net	59	1.00	-275	75	-181	159	-680	-1,107	-243	-2,358
Income Tax Expense	356	230	715	-71	-964	-795	293	-134	234	-421
Net Income / (Loss) Discontinued Operations	-21	2.00	1.00	-2.00	12	-26	-5.00	17	-8.00	7.00
Net Income / (Loss) Attributable to Noncontrolling Interest	15	8.00	13	11	6.00	9.00	8.00	7.00	8.00	8.00
Basic Earnings per Share	$1.54	$0.88	$0.98	$0.41	($0.42)	($0.59)	$0.55	$0.01	$0.79	$0.07
Weighted Average Basic Shares Outstanding	5.61B	5.61B	5.63B	5.65B	5.65B	5.64B	5.66B	5.67B	5.67B	5.66B
Diluted Earnings per Share	$1.51	$0.86	$0.97	$0.41	($0.42)	($0.59)	$0.55	$0.01	$0.78	$0.07
Weighted Average Diluted Shares Outstanding	5.72B	5.73B	5.73B	5.71B	5.65B	5.71B	5.70B	5.70B	5.71B	5.70B
Weighted Average Basic & Diluted Shares Outstanding	5.61B	5.62B	5.65B	5.65B	5.65B	5.65B	5.67B	5.67B	5.67B	5.67B

This table details how cash moves in and out of Pfizer's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-5,274	-1,042	-1,235	-89	125	475	159	-1,515	2,448	-1,810
Net Cash From Operating Activities	14,688	16,192	16,802	15,827	12,588	14,403	32,580	29,267	8,700	12,744
Net Cash From Continuing Operating Activities	13,883	16,192	16,798	8,875	7,015	10,540	32,922	29,267	8,701	12,743
Net Income / (Loss) Continuing Operations	6,986	7,246	21,355	3,860	10,738	6,666	22,459	31,401	2,172	8,051
Consolidated Net Income / (Loss)	6,986	7,246	21,355	11,188	16,056	9,195	22,025	31,407	2,158	8,062
Net Income / (Loss) Discontinued Operations	-	-	-	7,328	5,318	2,529	-434	6.00	-15	11
Depreciation Expense	5,157	5,757	6,269	6,150	5,755	4,681	5,191	5,064	6,290	7,013
Non-Cash Adjustments To Reconcile Net Income	1,019	3,091	914	1,402	-5,813	1,077	-3,238	2,205	5,853	2,847
Changes in Operating Assets and Liabilities, net	721	98	-11,736	-2,538	-3,664	-1,882	8,511	-9,403	-5,614	-5,168
Net Cash From Investing Activities	-2,980	-7,791	-4,740	4,525	-3,945	-4,271	-22,546	-15,783	-32,278	2,652
Net Cash From Continuing Investing Activities	-8,748	-7,791	-4,740	4,584	-3,825	-4,162	-22,534	-15,783	-32,277	2,654
Purchase of Property, Plant & Equipment	-1,397	-1,823	-1,956	-1,984	-2,046	-2,226	-2,711	-3,236	-3,907	-2,909
Acquisitions	-16,565	-18,544	-1,261	-152	-10,861	0.00	0.00	-22,997	-43,430	0.00
Purchase of Investments	-38,123	-23,968	-18,133	-17,391	-7,036	-14,402	-39,525	-38,297	-31,178	-10,313
Divestitures	-	-	-	-	-	-	-	0.00	0.00	7,040
Sale and/or Maturity of Investments	46,993	36,464	15,939	23,825	16,340	12,730	20,008	48,939	46,417	8,834
Other Investing Activities, net	344	80	671	287	-223	-265	-305	-192	-179	2.00
Net Cash From Financing Activities	-10,409	-9,228	-13,350	-20,441	-8,485	-9,649	-9,816	-14,834	26,066	-17,140
Net Cash From Continuing Financing Activities	-10,409	-9,228	-13,348	-20,441	-8,485	-21,640	-9,816	-14,834	26,067	-17,140
Repayment of Debt	-4,129	-13,318	-16,712	-10,208	-15,526	-26,644	-1,988	-7,520	-3,203	-13,945
Repurchase of Common Equity	-6,160	-5,000	-5,000	-12,198	-8,865	0.00	0.00	-2,000	0.00	0.00
Payment of Dividends	-6,940	-7,317	-7,659	-7,978	-8,043	-8,440	-8,729	-8,983	-9,247	-9,512
Issuance of Debt	5,557	15,388	15,160	8,685	23,948	13,445	901	3,669	38,517	6,317
Other Net Changes in Cash	-	-215	53	-	-32	-8.00	-59	-165	-40	-66
Cash Interest Paid	1,302	1,113	1,319	1,349	1,629	1,621	1,465	1,496	2,349	3,405
Cash Income Taxes Paid	2,383	2,521	2,489	3,655	3,664	3,153	7,427	7,867	3,147	3,605

This table details how cash moves in and out of Pfizer's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-487	-869	1,754	475	535	-316	-2,137	343	29	-45
Net Cash From Operating Activities	5,974	8,582	1,212	-1,208	3,456	5,240	1,090	-1,781	6,714	6,721
Net Cash From Continuing Operating Activities	5,968	8,582	1,211	-1,209	3,458	5,241	1,091	-1,781	6,713	6,720
Net Income / (Loss) Continuing Operations	8,644	5,001	5,555	2,340	-2,388	-3,335	3,128	31	4,481	411
Consolidated Net Income / (Loss)	8,623	5,003	5,556	2,338	-2,376	-3,360	3,123	48	4,473	418
Net Income / (Loss) Discontinued Operations	-22	2.00	1.00	-2.00	12	-26	-5.00	17	-8.00	7.00
Depreciation Expense	1,183	1,519	1,487	1,573	1,560	1,670	1,736	1,731	1,755	1,791
Non-Cash Adjustments To Reconcile Net Income	665	-15	274	-333	5,598	314	4.00	775	80	1,988
Changes in Operating Assets and Liabilities, net	-4,523	2,077	-6,105	-4,789	-1,312	6,592	-3,777	-4,318	397	2,530
Net Cash From Investing Activities	-627	-4,410	3,315	-25,485	888	-10,996	1,732	4,600	-2,057	-1,623
Net Cash From Continuing Investing Activities	-625	-4,411	3,316	-25,486	890	-10,997	1,731	4,601	-2,058	-1,620
Purchase of Property, Plant & Equipment	-841	-1,001	-1,139	-914	-810	-1,044	-704	-637	-651	-917
Purchase of Investments	-11,067	-6,969	-6,716	-14,382	-9,206	-874	-832	-530	-2,670	-6,281
Divestitures	-	-	0.00	-	-	-	3,491	-	-	3,549
Sale and/or Maturity of Investments	11,392	20,323	11,189	-9,640	10,556	34,312	-224	5,786	1,258	2,014
Other Investing Activities, net	-109	8.00	-18	-525	350	14	0.00	-18	5.00	15
Net Cash From Financing Activities	-5,761	-5,015	-2,771	27,174	-3,779	5,442	-4,931	-2,459	-4,636	-5,114
Net Cash From Continuing Financing Activities	-5,761	-5,015	-2,771	27,175	-3,779	5,442	-4,931	-2,459	-4,636	-5,114
Repayment of Debt	-3,882	-1,682	-705	-1,140	-1,337	-21	-1,964	-5,587	-2,928	-3,466
Payment of Dividends	-2,245	-2,245	-2,303	-2,315	-2,314	-2,315	-2,372	-2,380	-2,380	-2,380
Issuance of Debt	366	-1,088	237	30,630	-128	7,778	-595	5,508	672	732
Other Net Changes in Cash	-72	-26	-2.00	-5.00	-32	-1.00	-28	-18	9.00	-29
Cash Interest Paid	388	347	479	373	399	1,098	448	1,103	313	1,541
Cash Income Taxes Paid	1,821	2,948	329	1,696	882	240	184	2,502	486	433

This table presents Pfizer's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	167,381	171,615	171,797	159,422	167,594	154,229	181,475	197,205	226,501	213,396
Total Current Assets	43,804	38,949	41,142	49,926	32,803	35,067	59,693	51,259	43,333	50,358
Cash & Equivalents	3,641	2,595	1,342	1,139	1,121	1,786	1,944	416	2,853	1,043
Short-Term Investments	19,649	15,255	18,650	17,694	8,525	10,437	29,125	22,316	9,837	19,434
Accounts Receivable	8,176	8,225	8,221	8,025	6,772	7,913	11,479	10,952	11,566	11,463
Inventories, net	7,513	6,783	7,578	7,508	7,068	8,020	9,059	8,981	10,189	10,851
Current Deferred & Refundable Income Taxes	2,662	3,041	3,050	3,374	2,736	3,264	4,266	3,577	3,978	3,314
Other Current Assets	2,154	2,249	2,289	2,461	2,357	3,646	3,820	5,017	4,911	4,253
Plant, Property, & Equipment, net	13,766	13,318	13,865	13,385	12,969	13,745	14,882	16,274	18,940	18,393
Total Noncurrent Assets	109,811	119,348	116,790	96,113	121,822	105,417	106,900	129,670	164,228	144,644
Long-Term Investments	15,999	7,116	7,015	2,767	20,147	20,262	21,526	15,069	15,368	2,227
Goodwill	48,242	54,449	55,952	53,411	48,202	49,556	49,208	51,375	67,783	68,527
Intangible Assets	40,356	52,648	48,741	35,211	33,936	28,337	25,146	43,370	64,900	55,411
Noncurrent Deferred & Refundable Income Taxes	1,794	1,812	1,855	1,924	1,911	2,383	3,341	6,693	3,706	8,662
Other Noncurrent Operating Assets	3,420	3,323	3,227	2,800	4,199	4,879	7,679	13,163	12,471	9,817
Total Liabilities & Shareholders' Equity	140,505	171,615	171,797	159,422	167,594	154,229	181,476	197,205	226,501	213,396
Total Liabilities	75,507	111,775	100,141	95,664	104,148	90,756	104,013	101,288	137,213	124,899
Total Current Liabilities	29,399	31,115	30,427	31,858	37,304	25,920	42,671	42,138	47,794	42,995
Short-Term Debt	10,159	10,688	9,953	8,831	16,195	2,703	2,241	2,945	10,350	6,946
Accounts Payable	3,620	4,536	4,656	4,674	3,887	4,283	5,578	6,809	6,710	5,633
Dividends Payable	1,852	1,944	2,029	2,047	2,104	2,162	2,249	2,303	2,372	2,437
Current Deferred Revenue	-	-	-	-	-	1,113	3,067	2,520	2,700	1,511
Current Deferred & Payable Income Tax Liabilities	418	437	477	1,265	980	1,049	1,266	1,587	2,349	2,910
Current Employee Benefit Liabilities	2,359	2,487	2,196	2,397	2,390	3,049	3,332	3,407	2,776	3,838
Other Current Liabilities	10,990	11,023	11,115	10,754	9,334	11,561	24,939	22,568	20,537	19,720
Total Noncurrent Liabilities	46,108	80,660	69,714	63,806	66,844	64,836	61,342	59,149	89,418	81,904
Long-Term Debt	28,740	31,398	33,538	32,909	35,955	37,133	36,195	32,884	61,538	57,405
Noncurrent Deferred & Payable Income Tax Liabilities	3,992	34,753	22,597	18,437	17,778	15,623	11,680	10,835	9,174	8,234
Noncurrent Employee Benefit Liabilities	8,119	8,172	7,430	6,610	6,217	5,411	3,724	2,250	2,167	2,115
Other Noncurrent Operating Liabilities	5,257	6,337	6,149	5,850	6,894	6,669	9,743	13,180	16,539	14,150
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	64,998	59,840	71,656	63,758	63,447	63,473	77,462	95,916	89,288	88,497
Total Preferred & Common Equity	64,720	59,544	71,308	63,407	63,143	63,238	77,200	95,661	89,014	88,203
Total Common Equity	64,694	59,520	71,287	63,388	63,125	63,238	77,200	95,661	89,014	88,203
Common Stock	81,475	83,146	84,742	86,720	87,896	89,144	91,064	92,278	93,109	94,083
Retained Earnings	71,993	71,774	85,291	89,554	97,670	90,392	103,394	125,656	118,353	116,725
Treasury Stock	-79,252	-84,364	-89,425	-101,610	-110,801	-110,988	-111,361	-113,969	-114,487	-114,763
Accumulated Other Comprehensive Income / (Loss)	-9,522	-11,036	-9,321	-11,275	-11,640	-5,310	-5,897	-8,304	-7,961	-7,842
Noncontrolling Interest	278	296	348	351	303	235	262	256	274	294

This table presents Pfizer's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Total Assets	195,350	197,205	195,617	220,168	215,021	226,501	221,095	216,193	219,476	213,396
Total Current Assets	70,403	51,259	50,078	73,347	74,012	43,333	42,415	37,825	43,223	50,358
Cash & Equivalents	1,298	416	2,166	2,632	3,148	2,853	719	1,052	1,092	1,043
Short-Term Investments	34,825	22,316	17,806	42,153	41,033	9,837	11,209	6,048	8,860	19,434
Accounts Receivable	16,076	10,952	12,305	10,231	11,086	11,566	10,989	11,393	14,451	11,463
Inventories, net	9,513	8,981	9,541	10,310	10,204	10,189	10,892	11,447	11,721	10,851
Current Deferred & Refundable Income Taxes	2,544	3,577	3,140	3,194	3,917	3,978	4,233	3,694	3,243	3,314
Other Current Assets	6,149	5,017	5,120	4,828	4,624	4,911	4,372	4,190	3,855	4,253
Plant, Property, & Equipment, net	15,441	16,274	17,052	17,488	17,862	18,940	18,803	18,957	18,541	18,393
Total Noncurrent Assets	109,506	129,670	128,488	129,333	123,148	164,228	159,878	159,410	157,713	144,644
Long-Term Investments	13,888	15,069	14,743	15,066	14,239	15,368	11,613	11,148	10,762	2,227
Goodwill	49,441	51,375	51,476	51,572	51,527	67,783	69,297	68,445	68,570	68,527
Intangible Assets	28,151	43,370	42,002	41,406	40,224	64,900	62,829	61,240	59,986	55,411
Noncurrent Deferred & Refundable Income Taxes	7,136	6,693	7,302	8,261	8,350	3,706	4,942	7,867	7,909	8,662
Other Noncurrent Operating Assets	10,890	13,163	12,965	13,028	8,808	12,471	11,197	10,710	10,486	9,817
Total Liabilities & Shareholders' Equity	195,350	197,205	195,617	220,168	215,021	226,501	221,095	216,193	219,476	213,396
Total Liabilities	102,459	101,288	94,381	120,875	117,817	137,213	128,537	128,218	126,918	124,899
Total Current Liabilities	44,314	42,138	36,562	34,647	31,136	47,794	40,497	43,819	43,211	42,995
Short-Term Debt	4,040	2,945	4,188	3,985	2,548	10,350	8,232	11,944	9,699	6,946
Accounts Payable	6,267	6,809	6,123	6,081	5,338	6,710	5,591	5,106	5,314	5,633
Dividends Payable	2,245	2,303	0.00	2,315	0.00	2,372	0.00	2,380	0.00	2,437
Current Deferred Revenue	6,191	2,520	1,750	1,286	2,204	2,700	2,502	2,528	2,020	1,511
Current Deferred & Payable Income Tax Liabilities	3,071	1,587	1,969	2,928	1,898	2,349	3,192	2,884	2,877	2,910
Current Employee Benefit Liabilities	2,852	3,407	2,277	1,972	2,372	2,776	2,192	2,566	3,383	3,838
Other Current Liabilities	19,647	22,568	20,255	16,079	16,776	20,537	18,788	16,410	19,917	19,720
Total Noncurrent Liabilities	58,145	59,149	57,819	86,227	86,680	89,418	88,039	84,400	83,707	81,904
Long-Term Debt	32,629	32,884	31,704	61,356	61,048	61,538	61,307	57,506	58,002	57,405
Noncurrent Deferred & Payable Income Tax Liabilities	10,317	10,835	10,927	9,284	9,224	9,174	9,534	8,759	8,063	8,234
Noncurrent Employee Benefit Liabilities	2,960	2,250	2,179	2,184	2,166	2,167	2,076	2,040	2,073	2,115
Other Noncurrent Operating Liabilities	12,239	13,180	13,009	13,403	14,242	16,539	15,122	16,095	15,569	14,150
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	92,891	95,916	101,236	99,293	97,204	89,288	92,558	87,975	92,558	88,497
Total Preferred & Common Equity	92,631	95,661	100,970	99,019	96,934	89,014	92,282	87,700	92,286	88,203
Total Common Equity	92,632	95,661	100,971	99,019	96,934	89,014	92,282	87,700	92,285	88,203
Common Stock	91,835	92,278	92,631	92,807	92,974	93,109	93,477	93,677	93,957	94,083
Retained Earnings	122,967	125,656	131,102	128,796	126,411	118,353	121,318	116,596	121,059	116,725
Treasury Stock	-113,945	-113,969	-114,473	-114,482	-114,485	-114,487	-114,755	-114,757	-114,760	-114,763
Accumulated Other Comprehensive Income / (Loss)	-8,225	-8,304	-8,289	-8,102	-7,966	-7,961	-7,758	-7,816	-7,971	-7,842
Noncontrolling Interest	259	256	266	274	270	274	276	275	272	294

This table displays calculated financial ratios and metrics derived from Pfizer's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.52%	8.13%	-0.53%	-22.30%	0.20%	1.82%	95.16%	24.46%	-41.14%	6.84%
EBITDA Growth	-20.57%	-0.09%	31.65%	-47.53%	-7.97%	30.66%	151.77%	34.88%	-81.54%	104.66%
EBIT Growth	-26.76%	-6.84%	47.34%	-70.78%	-10.63%	119.02%	245.47%	42.84%	-96.96%	659.04%
NOPAT Growth	-6.81%	14.27%	126.50%	-74.41%	4.48%	22.81%	129.69%	80.25%	-91.88%	374.11%
Net Income Growth	-23.80%	3.72%	194.71%	-47.61%	43.51%	-42.73%	139.53%	42.60%	-93.13%	273.59%
EPS Growth	-21.83%	5.41%	200.85%	-46.88%	50.80%	-42.20%	136.20%	42.08%	-93.24%	281.08%
Operating Cash Flow Growth	-14.02%	10.24%	3.77%	-5.80%	-20.47%	14.42%	126.20%	-10.17%	-70.27%	46.48%
Free Cash Flow Firm Growth	-242.66%	192.73%	-54.33%	54.30%	-34.91%	-36.47%	238.44%	-93.44%	-2,300.11%	141.96%
Invested Capital Growth	65.55%	-16.31%	15.43%	-13.36%	-6.97%	0.43%	-10.19%	46.83%	40.78%	-2.15%
Revenue Q/Q Growth	1.94%	-0.79%	0.14%	-23.51%	1.71%	29.89%	18.02%	1.30%	-14.03%	7.16%
EBITDA Q/Q Growth	-12.76%	9.79%	1.09%	-51.52%	13.56%	260.78%	13.16%	4.20%	-55.61%	39.26%
EBIT Q/Q Growth	-19.40%	15.70%	1.45%	-73.92%	72.37%	583.98%	15.18%	4.26%	-89.85%	105.45%
NOPAT Q/Q Growth	0.37%	-1.43%	123.11%	-74.84%	26.28%	326.34%	12.83%	7.27%	-73.82%	139.28%
Net Income Q/Q Growth	-16.75%	15.07%	116.89%	-53.09%	-1.22%	18.42%	13.00%	5.41%	-79.49%	88.19%
EPS Q/Q Growth	-16.54%	15.84%	117.28%	-52.78%	-1.74%	18.98%	12.90%	5.19%	-79.67%	88.00%
Operating Cash Flow Q/Q Growth	-4.56%	7.60%	6.65%	-12.93%	-7.15%	14.79%	0.90%	10.03%	-27.75%	13.15%
Free Cash Flow Firm Q/Q Growth	-7,467.04%	336.40%	-73.37%	13.74%	210.05%	77.99%	-34.91%	-88.99%	-247.07%	148.08%
Invested Capital Q/Q Growth	-1.38%	-32.77%	9.00%	-14.15%	-21.19%	-18.75%	-1.79%	17.66%	32.34%	-4.99%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	80.25%	76.67%	78.63%	77.99%	80.31%	79.63%	62.08%	66.05%	58.10%	71.94%
EBITDA Margin	28.91%	26.71%	35.35%	23.87%	21.92%	28.13%	36.29%	39.33%	12.34%	23.63%
Operating Margin	24.20%	22.99%	26.11%	13.89%	16.40%	19.81%	23.91%	35.37%	2.15%	19.51%
EBIT Margin	18.35%	15.81%	23.42%	8.81%	7.85%	16.90%	29.91%	34.32%	1.77%	12.61%
Profit (Net Income) Margin	14.30%	13.72%	40.64%	27.40%	39.25%	22.08%	27.10%	31.04%	3.62%	12.67%
Tax Burden Percent	77.93%	86.77%	173.55%	311.30%	141.82%	130.69%	90.60%	90.43%	203.97%	100.49%
Interest Burden Percent	100.01%	100.00%	100.01%	99.97%	352.35%	99.99%	100.00%	100.01%	100.09%	100.00%
Effective Tax Rate	22.20%	13.45%	-73.54%	-7.40%	5.15%	5.26%	7.62%	9.58%	-105.39%	-0.35%
Return on Invested Capital (ROIC)	12.29%	12.26%	28.30%	7.24%	8.44%	10.73%	25.92%	40.00%	2.27%	9.29%
ROIC Less NNEP Spread (ROIC-NNEP)	-21.55%	-1.75%	14.95%	38.26%	90.65%	25.45%	-313.59%	56.45%	0.25%	-0.44%
Return on Net Nonoperating Assets (RNNOA)	-2.06%	-0.66%	4.18%	9.28%	16.80%	3.76%	5.34%	-3.77%	0.06%	-0.22%
Return on Equity (ROE)	10.23%	11.61%	32.48%	16.52%	25.24%	14.49%	31.26%	36.23%	2.33%	9.07%
Cash Return on Invested Capital (CROIC)	-37.08%	30.03%	13.97%	21.56%	15.66%	10.30%	36.65%	2.06%	-31.60%	11.46%
Operating Return on Assets (OROA)	5.35%	4.93%	7.17%	2.17%	1.97%	4.37%	14.48%	18.34%	0.50%	3.65%
Return on Assets (ROA)	4.17%	4.28%	12.44%	6.76%	9.82%	5.71%	13.12%	16.59%	1.02%	3.67%
Return on Common Equity (ROCE)	10.18%	11.55%	32.31%	16.43%	25.11%	14.43%	31.15%	36.12%	2.32%	9.04%
Return on Equity Simple (ROE_SIMPLE)	10.79%	12.17%	29.95%	17.64%	25.43%	14.54%	28.53%	32.83%	2.42%	9.14%
Net Operating Profit after Tax (NOPAT)	9,199	10,512	23,810	6,092	6,364	7,816	17,953	32,359	2,627	12,454
NOPAT Margin	18.83%	19.90%	45.31%	14.92%	15.56%	18.77%	22.09%	31.98%	4.41%	19.57%
Net Nonoperating Expense Percent (NNEP)	33.84%	14.02%	13.35%	-31.02%	-82.21%	-14.72%	339.51%	-16.45%	2.02%	9.73%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	24.56%	1.63%	8.15%
Cost of Revenue to Revenue	19.75%	23.33%	21.37%	22.01%	19.69%	20.37%	37.92%	33.95%	41.90%	28.06%
SG&A Expenses to Revenue	30.31%	28.10%	28.17%	30.89%	31.11%	27.84%	15.63%	13.52%	24.80%	23.15%
R&D to Revenue	15.74%	14.94%	14.62%	19.01%	20.50%	22.55%	17.01%	12.24%	18.26%	17.18%
Operating Expenses to Revenue	56.05%	53.68%	52.52%	64.09%	63.91%	59.82%	38.18%	30.68%	55.95%	52.44%
Earnings before Interest and Taxes (EBIT)	8,964	8,351	12,304	3,595	3,213	7,037	24,311	34,727	1,057	8,023
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	14,121	14,108	18,573	9,745	8,968	11,718	29,502	39,791	7,347	15,036
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.18	2.43	2.31	3.15	2.82	2.76	3.81	2.67	1.69	1.68
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	103.26	278.47	0.00	0.00
Price to Revenue (P/Rev)	2.89	2.74	3.14	4.89	4.35	4.19	3.62	2.52	2.53	2.32
Price to Earnings (P/E)	20.26	20.06	7.73	17.88	11.09	19.06	13.37	8.13	71.12	18.42
Dividend Yield	4.90%	5.03%	4.63%	3.94%	4.48%	4.84%	2.98%	3.52%	6.14%	6.44%
Earnings Yield	4.94%	4.99%	12.93%	5.59%	9.02%	5.25%	7.48%	12.30%	1.41%	5.43%
Enterprise Value to Invested Capital (EV/IC)	1.51	2.08	2.01	2.82	2.76	2.50	4.27	2.63	1.44	1.43
Enterprise Value to Revenue (EV/Rev)	2.88	3.07	3.46	5.39	4.90	4.37	3.44	2.50	3.27	2.98
Enterprise Value to EBITDA (EV/EBITDA)	9.98	11.50	9.78	22.57	22.35	15.55	9.49	6.37	26.52	12.63
Enterprise Value to EBIT (EV/EBIT)	15.72	19.42	14.76	61.18	62.38	25.89	11.52	7.30	184.30	23.66
Enterprise Value to NOPAT (EV/NOPAT)	15.32	15.43	7.63	36.11	31.49	23.31	15.60	7.83	74.16	15.24
Enterprise Value to Operating Cash Flow (EV/OCF)	9.59	10.02	10.81	13.90	15.92	12.65	8.59	8.66	22.39	14.90
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	6.30	15.45	12.13	16.98	24.29	11.03	152.22	0.00	12.35
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.60	0.70	0.61	0.65	0.82	0.63	0.50	0.37	0.81	0.73
Long-Term Debt to Equity	0.44	0.52	0.47	0.52	0.57	0.59	0.47	0.34	0.69	0.65
Financial Leverage	0.10	0.37	0.28	0.24	0.19	0.15	-0.02	-0.07	0.25	0.51
Leverage Ratio	2.45	2.72	2.61	2.45	2.57	2.54	2.38	2.18	2.29	2.47
Compound Leverage Factor	2.45	2.72	2.61	2.45	9.06	2.54	2.38	2.18	2.29	2.47
Debt to Total Capital	37.44%	41.29%	37.77%	39.56%	45.11%	38.56%	33.16%	27.20%	44.60%	42.10%
Short-Term Debt to Total Capital	9.78%	10.49%	8.64%	8.37%	14.01%	2.62%	1.93%	2.24%	6.42%	4.54%
Long-Term Debt to Total Capital	27.66%	30.80%	29.13%	31.19%	31.10%	35.94%	31.23%	24.96%	38.18%	37.56%
Preferred Equity to Total Capital	0.03%	0.02%	0.02%	0.02%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.27%	0.29%	0.30%	0.33%	0.26%	0.23%	0.23%	0.19%	0.17%	0.19%
Common Equity to Total Capital	62.27%	58.40%	61.91%	60.08%	54.61%	61.21%	66.61%	72.61%	55.23%	57.71%
Debt to EBITDA	2.75	2.98	2.34	4.28	5.82	3.40	1.30	0.90	9.78	4.28
Net Debt to EBITDA	-0.03	1.21	0.89	2.07	2.49	0.63	-0.48	-0.05	5.97	2.77
Long-Term Debt to EBITDA	2.04	2.23	1.81	3.38	4.01	3.17	1.23	0.83	8.38	3.82
Debt to NOPAT	4.23	4.00	1.83	6.85	8.19	5.10	2.14	1.11	27.37	5.17
Net Debt to NOPAT	-0.04	1.63	0.69	3.31	3.51	0.94	-0.79	-0.06	16.69	3.34
Long-Term Debt to NOPAT	3.12	2.99	1.41	5.40	5.65	4.75	2.02	1.02	23.43	4.61
Altman Z-Score	2.29	1.89	2.30	2.50	2.12	2.47	3.50	3.55	1.65	1.94
Noncontrolling Interest Sharing Ratio	0.48%	0.50%	0.52%	0.55%	0.54%	0.44%	0.35%	0.30%	0.29%	0.32%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.49	1.25	1.35	1.57	0.88	1.35	1.40	1.22	0.91	1.17
Quick Ratio	1.07	0.84	0.93	0.84	0.44	0.78	1.00	0.80	0.51	0.74
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-27,754	25,737	11,755	18,138	11,806	7,501	25,387	1,664	-36,619	15,366
Operating Cash Flow to CapEx	1,051.40%	888.21%	859.00%	797.73%	615.25%	647.04%	1,201.77%	904.42%	222.68%	438.09%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.29	0.31	0.31	0.25	0.25	0.26	0.48	0.53	0.28	0.29
Accounts Receivable Turnover	5.89	6.44	6.39	5.03	5.53	5.67	8.38	9.02	5.29	5.53
Inventory Turnover	1.46	1.72	1.56	1.19	1.11	1.12	3.61	3.81	2.60	1.70
Fixed Asset Turnover	3.83	3.90	3.87	3.00	3.10	3.12	5.68	6.49	3.38	3.41
Accounts Payable Turnover	2.83	3.02	2.44	1.93	1.88	2.08	6.25	5.55	3.69	2.89
Days Sales Outstanding (DSO)	61.93	56.66	57.12	72.62	66.02	64.34	43.54	40.46	69.01	66.05
Days Inventory Outstanding (DIO)	249.24	211.74	233.42	306.35	330.29	324.56	101.13	95.86	140.20	215.10
Days Payable Outstanding (DPO)	129.20	120.80	149.41	189.47	193.99	175.75	58.39	65.82	98.87	126.19
Cash Conversion Cycle (CCC)	181.97	147.60	141.14	189.51	202.31	213.16	86.28	70.50	110.33	154.97
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	93,328	78,103	90,158	78,112	72,670	72,985	65,551	96,246	135,492	132,580
Invested Capital Turnover	0.65	0.62	0.62	0.49	0.54	0.57	1.17	1.25	0.51	0.47
Increase / (Decrease) in Invested Capital	36,953	-15,225	12,055	-12,046	-5,442	315	-7,434	30,695	39,246	-2,912
Enterprise Value (EV)	140,905	162,174	181,627	219,960	200,436	182,177	279,990	253,360	194,808	189,841
Market Capitalization	140,991	144,734	164,774	199,450	177,759	174,591	293,887	255,076	150,704	147,900
Book Value per Share	$10.48	$9.81	$11.96	$10.97	$11.41	$11.38	$13.75	$17.04	$15.76	$15.56
Tangible Book Value per Share	($3.87)	($7.84)	($5.60)	($4.37)	($3.44)	($2.64)	$0.51	$0.16	($7.73)	($6.31)
Total Capital	103,897	101,926	115,147	105,498	115,597	103,309	115,898	131,745	161,176	152,848
Total Debt	38,899	42,086	43,491	41,740	52,150	39,836	38,436	35,829	71,888	64,351
Total Long-Term Debt	28,740	31,398	33,538	32,909	35,955	37,133	36,195	32,884	61,538	57,405
Net Debt	-390	17,120	16,484	20,140	22,357	7,351	-14,159	-1,972	43,830	41,647
Capital Expenditures (CapEx)	1,397	1,823	1,956	1,984	2,046	2,226	2,711	3,236	3,907	2,909
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,274	672	676	8,066	2,048	-373	-11,806	-10,666	-6,801	-6,168
Debt-free Net Working Capital (DFNWC)	24,564	18,522	20,668	26,899	11,694	11,850	19,263	12,066	5,889	14,309
Net Working Capital (NWC)	14,405	7,834	10,715	18,068	-4,501	9,147	17,022	9,121	-4,461	7,363
Net Nonoperating Expense (NNE)	2,213	3,266	2,455	-5,096	-9,692	-1,379	-4,072	952	469	4,392
Net Nonoperating Obligations (NNO)	28,330	18,263	18,502	14,354	9,223	9,512	-11,911	330	46,204	44,083
Total Depreciation and Amortization (D&A)	5,157	5,757	6,269	6,150	5,755	4,681	5,191	5,064	6,290	7,013
Debt-free, Cash-free Net Working Capital to Revenue	2.61%	1.27%	1.29%	19.76%	5.01%	-0.90%	-14.52%	-10.54%	-11.42%	-9.69%
Debt-free Net Working Capital to Revenue	50.28%	35.06%	39.33%	65.89%	28.59%	28.45%	23.70%	11.93%	9.89%	22.49%
Net Working Capital to Revenue	29.49%	14.83%	20.39%	44.26%	-11.00%	21.96%	20.94%	9.02%	-7.49%	11.57%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.13	$1.18	$3.57	$1.90	$2.92	$1.73	$3.92	$5.59	$0.38	$1.42
Adjusted Weighted Average Basic Shares Outstanding	6.18B	6.09B	5.97B	5.87B	5.57B	5.56B	5.60B	5.61B	5.64B	5.66B
Adjusted Diluted Earnings per Share	$1.11	$1.17	$3.52	$1.87	$2.87	$1.71	$3.85	$5.47	$0.37	$1.41
Adjusted Weighted Average Diluted Shares Outstanding	6.26B	6.16B	6.06B	5.98B	5.68B	5.63B	5.71B	5.73B	5.71B	5.70B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$2.92	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	6.18B	5.95B	5.95B	5.55B	5.55B	5.58B	5.62B	5.62B	5.65B	5.67B
Normalized Net Operating Profit after Tax (NOPAT)	10,096	11,866	9,850	4,711	6,935	8,365	18,694	33,603	2,955	10,381
Normalized NOPAT Margin	20.67%	22.46%	18.75%	11.54%	16.95%	20.08%	23.00%	33.21%	4.96%	16.32%
Pre Tax Income Margin	18.35%	15.81%	23.42%	8.80%	27.68%	16.89%	29.91%	34.33%	1.78%	12.61%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	99.34%	100.98%	35.87%	71.31%	50.09%	91.79%	39.63%	28.60%	428.50%	117.99%
Augmented Payout Ratio	187.52%	169.98%	59.28%	180.34%	105.31%	91.79%	39.63%	34.97%	428.50%	117.99%

This table displays calculated financial ratios and metrics derived from Pfizer's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-5.81%	5.44%	-27.96%	-53.11%	-40.41%	-42.03%	-19.51%	2.12%	31.21%	21.92%
EBITDA Growth	10.90%	31.19%	-24.24%	-69.56%	-117.59%	-136.45%	-33.50%	-57.65%	461.10%	172.39%
EBIT Growth	14.78%	37.30%	-30.74%	-80.18%	-137.24%	-178.99%	-45.41%	-104.58%	240.69%	99.73%
NOPAT Growth	34.12%	79.81%	-29.15%	-78.54%	-125.84%	-160.08%	-35.31%	-68.97%	312.32%	154.73%
Net Income Growth	5.69%	47.54%	-29.40%	-76.41%	-127.55%	-167.16%	-43.79%	-97.95%	288.26%	112.44%
EPS Growth	6.34%	45.76%	-29.20%	-76.30%	-127.81%	-168.60%	-43.30%	-97.56%	285.71%	111.86%
Operating Cash Flow Growth	-44.83%	45.11%	-81.47%	-114.79%	-42.15%	-38.94%	-10.07%	-47.43%	94.27%	28.26%
Free Cash Flow Firm Growth	-121.92%	-351.64%	-361.82%	-1,519.09%	-252.76%	-64.40%	-45.49%	-24.52%	-42.30%	110.78%
Invested Capital Growth	22.56%	46.83%	37.74%	37.78%	25.17%	40.78%	35.29%	32.17%	36.30%	-2.15%
Revenue Q/Q Growth	-18.40%	11.03%	-23.89%	-29.64%	3.72%	7.99%	8.05%	-10.73%	33.27%	0.34%
EBITDA Q/Q Growth	-19.31%	-33.77%	14.97%	-50.46%	-146.64%	-37.22%	309.67%	-68.46%	297.73%	-72.49%
EBIT Q/Q Growth	-21.36%	-41.94%	19.94%	-63.81%	-247.73%	-23.18%	182.86%	-103.04%	4,634.62%	-100.23%
NOPAT Q/Q Growth	-18.53%	-41.83%	38.43%	-60.97%	-198.10%	-35.23%	205.35%	-81.28%	571.26%	-65.14%
Net Income Q/Q Growth	-13.00%	-41.98%	11.05%	-57.92%	-201.63%	-41.41%	192.95%	-98.46%	9,218.75%	-90.66%
EPS Q/Q Growth	-12.72%	-43.05%	12.79%	-57.73%	-202.44%	-40.48%	193.22%	-98.18%	7,700.00%	-91.03%
Operating Cash Flow Q/Q Growth	-26.88%	43.66%	-85.88%	-199.67%	386.09%	51.62%	-79.20%	-263.39%	476.98%	0.10%
Free Cash Flow Firm Q/Q Growth	-438.45%	-297.52%	16.01%	-21.75%	15.87%	-85.26%	24.33%	-4.20%	3.85%	114.04%
Invested Capital Q/Q Growth	5.23%	17.66%	6.41%	4.58%	-4.41%	32.34%	2.26%	2.16%	-1.42%	-4.99%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	73.22%	61.61%	73.57%	75.11%	31.29%	48.10%	77.29%	75.16%	70.27%	66.73%
EBITDA Margin	44.99%	26.84%	41.96%	29.54%	-13.28%	-16.88%	34.67%	12.25%	36.56%	10.02%
Operating Margin	39.50%	20.79%	35.40%	16.87%	-23.50%	-29.43%	27.57%	7.55%	28.01%	13.21%
EBIT Margin	39.77%	20.80%	33.91%	17.44%	-24.85%	-28.34%	23.00%	-0.78%	26.64%	-0.06%
Profit (Net Income) Margin	38.09%	19.91%	30.06%	17.97%	-17.61%	-23.06%	20.99%	0.36%	25.27%	2.35%
Tax Burden Percent	95.80%	95.64%	88.61%	103.04%	70.88%	81.38%	91.29%	-46.60%	94.87%	-4,180.00%
Interest Burden Percent	99.99%	100.08%	100.02%	100.00%	100.00%	100.00%	99.97%	99.04%	99.98%	90.91%
Effective Tax Rate	3.96%	4.40%	11.40%	-3.13%	0.00%	0.00%	8.56%	0.00%	4.96%	0.00%
Return on Invested Capital (ROIC)	51.02%	24.86%	33.06%	14.76%	-12.38%	-10.59%	11.48%	2.35%	13.07%	4.39%
ROIC Less NNEP Spread (ROIC-NNEP)	50.69%	24.74%	39.81%	6.95%	-7.09%	-12.13%	8.82%	0.21%	12.15%	1.68%
Return on Net Nonoperating Assets (RNNOA)	-6.10%	-1.65%	-1.55%	-0.07%	0.22%	-3.05%	2.15%	0.07%	3.34%	0.85%
Return on Equity (ROE)	44.93%	23.21%	31.51%	14.69%	-12.16%	-13.64%	13.63%	2.42%	16.41%	5.24%
Cash Return on Invested Capital (CROIC)	20.35%	2.06%	1.29%	-9.20%	-11.46%	-31.60%	-31.29%	-29.63%	-26.42%	11.46%
Operating Return on Assets (OROA)	21.21%	11.11%	16.65%	6.59%	-8.39%	-7.97%	6.06%	-0.20%	7.28%	-0.02%
Return on Assets (ROA)	20.32%	10.64%	14.76%	6.79%	-5.95%	-6.48%	5.53%	0.09%	6.91%	0.68%
Return on Common Equity (ROCE)	44.78%	23.14%	31.42%	14.65%	-12.12%	-13.60%	13.59%	2.41%	16.36%	5.23%
Return on Equity Simple (ROE_SIMPLE)	32.17%	0.00%	28.81%	21.73%	10.85%	0.00%	-0.30%	-2.92%	4.64%	0.00%
Net Operating Profit after Tax (NOPAT)	8,589	4,996	5,798	2,263	-2,220	-3,002	3,751	702	4,713	1,643
NOPAT Margin	37.94%	19.88%	31.36%	17.40%	-16.45%	-20.60%	25.21%	5.29%	26.62%	9.25%
Net Nonoperating Expense Percent (NNEP)	0.33%	0.12%	-6.76%	7.81%	-5.28%	1.54%	2.66%	2.13%	0.92%	2.71%
Return On Investment Capital (ROIC_SIMPLE)	-	3.79%	-	-	-	-1.86%	-	-	-	1.07%
Cost of Revenue to Revenue	26.78%	38.39%	26.43%	24.89%	68.71%	51.90%	22.71%	24.84%	29.73%	33.27%
SG&A Expenses to Revenue	14.98%	18.48%	18.49%	26.89%	24.32%	31.40%	23.49%	27.98%	18.33%	24.06%
R&D to Revenue	14.22%	14.68%	13.66%	20.61%	20.59%	19.82%	16.76%	20.34%	14.75%	17.59%
Operating Expenses to Revenue	33.71%	40.82%	38.17%	58.25%	54.80%	77.53%	49.72%	67.61%	42.26%	53.52%
Earnings before Interest and Taxes (EBIT)	9,002	5,227	6,269	2,269	-3,352	-4,129	3,422	-104	4,716	-11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	10,185	6,746	7,756	3,842	-1,792	-2,459	5,158	1,627	6,471	1,780
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.41	2.67	2.10	1.95	1.82	1.69	1.65	1.78	1.79	1.68
Price to Tangible Book Value (P/TBV)	14.82	278.47	28.27	32.01	34.12	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.23	2.52	2.27	2.47	2.55	2.53	2.77	2.83	2.78	2.32
Price to Earnings (P/E)	7.49	8.13	7.29	9.01	16.87	71.12	0.00	0.00	38.77	18.42
Dividend Yield	4.00%	3.52%	4.27%	4.73%	5.20%	6.14%	6.12%	6.02%	5.74%	6.44%
Earnings Yield	13.35%	12.30%	13.72%	11.10%	5.93%	1.41%	0.00%	0.00%	2.58%	5.43%
Enterprise Value to Invested Capital (EV/IC)	2.57	2.63	2.08	1.86	1.78	1.44	1.43	1.47	1.52	1.43
Enterprise Value to Revenue (EV/Rev)	2.10	2.50	2.29	2.54	2.63	3.27	3.62	3.77	3.57	2.98
Enterprise Value to EBITDA (EV/EBITDA)	5.50	6.37	5.72	6.98	11.01	26.52	41.80	82.01	19.64	12.63
Enterprise Value to EBIT (EV/EBIT)	6.30	7.30	6.68	8.75	17.51	184.30	0.00	0.00	54.32	23.66
Enterprise Value to NOPAT (EV/NOPAT)	6.96	7.83	7.30	9.54	18.17	74.16	0.00	0.00	40.75	15.24
Enterprise Value to Operating Cash Flow (EV/OCF)	7.89	8.66	8.91	13.68	15.14	22.39	23.14	25.96	18.83	14.90
Enterprise Value to Free Cash Flow (EV/FCFF)	13.89	152.22	186.80	0.00	0.00	0.00	0.00	0.00	0.00	12.35
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.39	0.37	0.35	0.66	0.65	0.81	0.75	0.79	0.73	0.73
Long-Term Debt to Equity	0.35	0.34	0.31	0.62	0.63	0.69	0.66	0.65	0.63	0.65
Financial Leverage	-0.12	-0.07	-0.04	-0.01	-0.03	0.25	0.24	0.33	0.27	0.51
Leverage Ratio	2.22	2.18	2.06	2.22	2.16	2.29	2.15	2.33	2.29	2.47
Compound Leverage Factor	2.22	2.19	2.06	2.22	2.16	2.29	2.15	2.31	2.29	2.25
Debt to Total Capital	28.30%	27.20%	26.17%	39.69%	39.55%	44.60%	42.90%	44.12%	42.24%	42.10%
Short-Term Debt to Total Capital	3.12%	2.24%	3.05%	2.42%	1.58%	6.42%	5.08%	7.59%	6.05%	4.54%
Long-Term Debt to Total Capital	25.18%	24.96%	23.12%	37.27%	37.97%	38.18%	37.82%	36.53%	36.19%	37.56%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.20%	0.19%	0.19%	0.17%	0.17%	0.17%	0.17%	0.17%	0.17%	0.19%
Common Equity to Total Capital	71.50%	72.61%	73.63%	60.14%	60.28%	55.23%	56.93%	55.71%	57.58%	57.71%
Debt to EBITDA	0.96	0.90	0.96	2.29	3.84	9.78	14.64	27.41	6.27	4.28
Net Debt to EBITDA	-0.35	-0.05	0.03	0.19	0.31	5.97	9.69	20.21	4.35	2.77
Long-Term Debt to EBITDA	0.85	0.83	0.85	2.15	3.69	8.38	12.91	22.69	5.37	3.82
Debt to NOPAT	1.22	1.11	1.23	3.13	6.34	27.37	-44.75	-29.09	13.01	5.17
Net Debt to NOPAT	-0.44	-0.06	0.04	0.26	0.52	16.69	-29.60	-21.44	9.03	3.34
Long-Term Debt to NOPAT	1.08	1.02	1.09	2.94	6.08	23.43	-39.45	-24.08	11.14	4.61
Altman Z-Score	3.01	3.06	2.95	2.38	2.23	1.57	1.79	1.71	1.89	1.82
Noncontrolling Interest Sharing Ratio	0.32%	0.30%	0.29%	0.29%	0.28%	0.29%	0.28%	0.29%	0.29%	0.32%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.59	1.22	1.37	2.12	2.38	0.91	1.05	0.86	1.00	1.17
Quick Ratio	1.18	0.80	0.88	1.59	1.78	0.51	0.57	0.42	0.56	0.74
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6,465	-25,699	-22,264	-27,106	-22,805	-42,248	-32,392	-33,752	-32,451	4,555
Operating Cash Flow to CapEx	710.34%	857.34%	106.41%	-132.17%	426.67%	501.92%	154.83%	-279.59%	1,031.34%	732.93%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.53	0.53	0.49	0.38	0.34	0.28	0.26	0.25	0.27	0.29
Accounts Receivable Turnover	7.14	9.02	7.30	6.18	5.10	5.29	4.71	5.10	4.65	5.53
Inventory Turnover	3.79	3.81	3.00	2.30	2.74	2.60	2.30	2.16	1.78	1.70
Fixed Asset Turnover	6.69	6.49	5.79	4.79	4.16	3.38	3.06	3.03	3.26	3.41
Accounts Payable Turnover	6.28	5.55	5.03	3.88	4.66	3.69	4.00	4.20	3.66	2.89
Days Sales Outstanding (DSO)	51.11	40.46	50.02	59.08	71.56	69.01	77.45	71.54	78.49	66.05
Days Inventory Outstanding (DIO)	96.22	95.86	121.81	158.99	133.07	140.20	159.04	168.89	205.15	215.10
Days Payable Outstanding (DPO)	58.12	65.82	72.57	94.09	78.32	98.87	91.18	86.84	99.67	126.19
Cash Conversion Cycle (CCC)	89.21	70.50	99.26	123.97	126.31	110.33	145.31	153.59	183.97	154.97
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	81,797	96,246	102,414	107,101	102,382	135,492	138,557	141,555	139,546	132,580
Invested Capital Turnover	1.34	1.25	1.05	0.85	0.75	0.51	0.46	0.44	0.49	0.47
Increase / (Decrease) in Invested Capital	15,054	30,695	28,062	29,369	20,585	39,246	36,143	34,454	37,164	-2,912
Enterprise Value (EV)	209,848	253,360	213,254	199,146	182,291	194,808	198,486	207,822	212,103	189,841
Market Capitalization	222,931	255,076	211,811	193,382	176,845	150,704	152,212	156,345	164,844	147,900
Book Value per Share	$16.51	$17.04	$17.97	$17.54	$17.17	$15.76	$16.31	$15.48	$16.29	$15.56
Tangible Book Value per Share	$2.68	$0.16	$1.33	$1.07	$0.92	($7.73)	($7.04)	($7.41)	($6.40)	($6.31)
Total Capital	129,560	131,745	137,128	164,634	160,800	161,176	162,097	157,425	160,259	152,848
Total Debt	36,669	35,829	35,892	65,341	63,596	71,888	69,539	69,450	67,701	64,351
Total Long-Term Debt	32,629	32,884	31,704	61,356	61,048	61,538	61,307	57,506	58,002	57,405
Net Debt	-13,342	-1,972	1,177	5,490	5,176	43,830	45,998	51,202	46,987	41,647
Capital Expenditures (CapEx)	841	1,001	1,139	914	810	1,044	704	637	651	917
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5,994	-10,666	-2,268	-2,100	1,243	-6,801	-1,778	-1,150	-241	-6,168
Debt-free Net Working Capital (DFNWC)	30,129	12,066	17,704	42,685	45,424	5,889	10,150	5,950	9,711	14,309
Net Working Capital (NWC)	26,089	9,121	13,516	38,700	42,876	-4,461	1,918	-5,994	12	7,363
Net Nonoperating Expense (NNE)	-34	-6.78	242	-75	156	358	628	654	240	1,225
Net Nonoperating Obligations (NNO)	-11,094	330	1,178	7,808	5,178	46,204	45,999	53,580	46,988	44,083
Total Depreciation and Amortization (D&A)	1,183	1,519	1,487	1,573	1,560	1,670	1,736	1,731	1,755	1,791
Debt-free, Cash-free Net Working Capital to Revenue	-6.00%	-10.54%	-2.43%	-2.68%	1.79%	-11.42%	-3.24%	-2.08%	-0.41%	-9.69%
Debt-free Net Working Capital to Revenue	30.17%	11.93%	19.00%	54.43%	65.57%	9.89%	18.49%	10.79%	16.36%	22.49%
Net Working Capital to Revenue	26.12%	9.02%	14.51%	49.35%	61.89%	-7.49%	3.49%	-10.87%	0.02%	11.57%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.54	$0.88	$0.98	$0.41	($0.42)	($0.59)	$0.55	$0.01	$0.79	$0.07
Adjusted Weighted Average Basic Shares Outstanding	5.61B	5.61B	5.63B	5.65B	5.65B	5.64B	5.66B	5.67B	5.67B	5.66B
Adjusted Diluted Earnings per Share	$1.51	$0.86	$0.97	$0.41	($0.42)	($0.59)	$0.55	$0.01	$0.78	$0.07
Adjusted Weighted Average Diluted Shares Outstanding	5.72B	5.73B	5.73B	5.71B	5.65B	5.71B	5.70B	5.70B	5.71B	5.70B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.61B	5.62B	5.65B	5.65B	5.65B	5.65B	5.67B	5.67B	5.67B	5.67B
Normalized Net Operating Profit after Tax (NOPAT)	8,780	5,756	5,806	1,686	-2,111	-1,206	3,844	1,580	5,010	2,168
Normalized NOPAT Margin	38.79%	22.90%	31.41%	12.96%	-15.65%	-8.28%	25.83%	11.89%	28.30%	12.20%
Pre Tax Income Margin	39.76%	20.81%	33.92%	17.44%	-24.85%	-28.34%	22.99%	-0.78%	26.64%	-0.06%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	29.96%	28.60%	31.06%	42.32%	87.23%	428.50%	-3,387.64%	-365.73%	220.52%	117.99%
Augmented Payout Ratio	36.67%	34.97%	31.06%	42.32%	87.23%	428.50%	-3,387.64%	-365.73%	220.52%	117.99%

Frequently Asked Questions About Pfizer's Financials

When does Pfizer's fiscal year end?

According to the most recent income statement we have on file, Pfizer's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Pfizer's net income changed over the last 9 years?

Pfizer's net income appears to be on an upward trend, with a most recent value of $8.06 billion in 2024, rising from $6.99 billion in 2015. The previous period was $2.16 billion in 2023.

What is Pfizer's operating income?

Pfizer's total operating income in 2024 was $12.41 billion, based on the following breakdown:

Total Gross Profit: $45.78 billion
Total Operating Expenses: $33.37 billion

How has Pfizer revenue changed over the last 9 years?

Over the last 9 years, Pfizer's total revenue changed from $48.85 billion in 2015 to $63.63 billion in 2024, a change of 30.2%.

How much debt does Pfizer have?

Pfizer's total liabilities were at $124.90 billion at the end of 2024, a 9.0% decrease from 2023, and a 65.4% increase since 2015.

How much cash does Pfizer have?

In the past 9 years, Pfizer's cash and equivalents has ranged from $416 million in 2022 to $3.64 billion in 2015, and is currently $1.04 billion as of their latest financial filing in 2024.

How has Pfizer's book value per share changed over the last 9 years?

Over the last 9 years, Pfizer's book value per share changed from 10.48 in 2015 to 15.56 in 2024, a change of 48.5%.

Related Companies

This page (NYSE:PFE) was last updated on 4/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pfizer (PFE) Financials

Frequently Asked Questions About Pfizer's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pfizer (PFE) Financials

Annual Income Statements for Pfizer

Quarterly Income Statements for Pfizer

Annual Cash Flow Statements for Pfizer

Quarterly Cash Flow Statements for Pfizer

Annual Balance Sheets for Pfizer

Quarterly Balance Sheets for Pfizer

Annual Metrics and Ratios for Pfizer

Quarterly Metrics and Ratios for Pfizer

Frequently Asked Questions About Pfizer's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools